Scarica l'app Stockscreener
0.593
3.13%
0.018
Dopo l'orario di chiusura:
.60
0.007
+1.18%
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics (OTLK) Seeks Permanent J-Code for LYTENAVA to Boost U.S. Commercial Launch - GuruFocus
Outlook Therapeutics applies for permanent J-code for LYTENAVA By Investing.com - Investing.com Canada
Outlook Therapeutics Submits HCPCS Level II Application to - GlobeNewswire
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Cash per share of Outlook Therapeutics, Inc. – HAN:41O - TradingView
Outlook Therapeutics, Inc. Revenue Breakdown – HAN:41O - TradingView
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - stocktwits.com
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - Stocktwits
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics, Inc.(NasdaqCM: OTLK) added to S&P Global BMI Index - marketscreener.com
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits
Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Outlook Therapeutics (OTLK) Edges Higher, Holding Above $0.65 SupportRatio Spread Trade - careplusvn.com
Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Australia
OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.50 - GuruFocus
Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Australia
Outlook Therapeutics CEO discusses LYTENAVA commercial launch - investing.com
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment - marketscreener.com
Only one FDA-approved eye medicine of its type exists in the U.S. It’s LYTENAVA. - Stock Titan
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA in Virtual Investor CEO Connect Segment - 富途牛牛
AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits
Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us
People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - stocktitan.net
Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com
Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView
Outlook Therapeutics Appoints Kevin Lundquist as CFO - Yahoo Finance
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):